PARP inhibitors and cancer therapy - early results and potential applications.
Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.